Terms: = Endocrine gland cancer AND BMPR1A, ACVRLK3, 657, ENSG00000107779, P36894, ALK3, CD292
115 results:
1. Interobserver agreement of pathologic classification and grading of tumoral intraductal pre-invasive neoplasms of the bile duct.
Nakanuma Y; Sato Y; Kakuda Y; Naito Y; Fukumura Y; Fukushima M; Minato H; Aishima S; Ohike N; Furukawa T
Ann Diagn Pathol; 2024 Apr; 69():152247. PubMed ID: 38128439
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic significance of PD-L1 expression in pancreatic cancer: evidence from an updated meta-analysis.
Liu C; Fan L; Wu Q; Shi Y; Sun X
Pol J Pathol; 2023; 74(3):151-160. PubMed ID: 37955534
[TBL] [Abstract] [Full Text] [Related]
3. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinoma.
Giaccherini M; Gori L; Gentiluomo M; Farinella R; Cervena K; Skieceviciene J; Dijk F; Capurso G; Vezakis A; Archibugi L; Chammas R; Hussein T; Tavano F; Hegyi P; Lovecek M; Izbicki JR; Brenner H; Mohelnikova-Duchonova B; Dell'Anna G; Kupcinskas J; Ermini S; Aoki MN; Neoptolemos JP; Gazouli M; Pasquali C; Pezzilli R; Talar-Wojnarowska R; Oliverius M; Al-Saeedi M; Lucchesi M; Furbetta N; Carrara S; van Eijck CHJ; Maleckas A; Milanetto AC; Lawlor RT; Schöttker B; Boggi U; Morelli L; Ginocchi L; Ponz de Leon Pisani R; Sperti C; Zerbi A; Arcidiacono PG; Uzunoglu FG; Bunduc S; Holleczek B; Gioffreda D; Małecka-Wojciesko E; Kiudelis M; Szentesi A; van Laarhoven HWM; Soucek P; Götz M; Erőss B; Cavestro GM; Basso D; Perri F; Landi S; Canzian F; Campa D
Carcinogenesis; 2023 Dec; 44(8-9):642-649. PubMed ID: 37670727
[TBL] [Abstract] [Full Text] [Related]
4. The auxiliary diagnosis of thyroid echogenic foci based on a deep learning segmentation model: A two-center study.
Liu Y; Chen C; Wang K; Zhang M; Yan Y; Sui L; Yao J; Zhu X; Wang H; Pan Q; Wang Y; Liang P; Xu D
Eur J Radiol; 2023 Oct; 167():111033. PubMed ID: 37595399
[TBL] [Abstract] [Full Text] [Related]
5. [Establishment and validation of a nomogram model for evaluating the metastasis of lymph nodes posterior to the right recurrent laryngeal nerve in papillary thyroid carcinoma].
Wang ZY; Chang QG; Guo HH; Du X; Liu YH; Yin DT
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(28):2175-2182. PubMed ID: 37482730
[No Abstract] [Full Text] [Related]
6. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
[No Abstract] [Full Text] [Related]
7. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
[TBL] [Abstract] [Full Text] [Related]
8. A protective factor against lymph node metastasis of papillary thyroid cancer: Female gender.
Shi P; Yang D; Liu Y; Zhao Z; Song J; Shi H; Wu Y; Jing S
Auris Nasus Larynx; 2023 Jun; 50(3):440-449. PubMed ID: 36253315
[TBL] [Abstract] [Full Text] [Related]
9. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract] [Full Text] [Related]
10. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract] [Full Text] [Related]
11. Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis.
Tang Q; Pan W; Peng L
PLoS One; 2022; 17(6):e0269995. PubMed ID: 35709179
[TBL] [Abstract] [Full Text] [Related]
12. Diagnostic Performance of the Ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound Risk Score in Women in the United States.
Jha P; Gupta A; Baran TM; Maturen KE; Patel-Lippmann K; Zafar HM; Kamaya A; Antil N; Barroilhet L; Sadowski EA
JAMA Netw Open; 2022 Jun; 5(6):e2216370. PubMed ID: 35679042
[TBL] [Abstract] [Full Text] [Related]
13. Value of 3-T MR imaging in intraductal papillary mucinous neoplasm with a concomitant invasive carcinoma.
Sotozono H; Kanki A; Yasokawa K; Yamamoto A; Sanai H; Moriya K; Tamada T
Eur Radiol; 2022 Dec; 32(12):8276-8284. PubMed ID: 35665843
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Impact of Inflammatory Markers PLR, LMR, PDW, MPV in Medullary Thyroid Carcinoma.
Li C; Zhang H; Li S; Zhang D; Li J; Dionigi G; Liang N; Sun H
Front Endocrinol (Lausanne); 2022; 13():861869. PubMed ID: 35350101
[TBL] [Abstract] [Full Text] [Related]
15. Ultrasound grayscale ratio: a reliable parameter for differentiating between papillary thyroid microcarcinoma and micronodular goiter.
Gong Y; Yao X; Yu L; Wei P; Han Z; Fang J; Ao W; Xu C
BMC Endocr Disord; 2022 Mar; 22(1):75. PubMed ID: 35331216
[TBL] [Abstract] [Full Text] [Related]
16. Novel Interactive Tool for Breast and Ovarian cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study.
Hibler EA; Fought AJ; Kershaw KN; Molsberry R; Nowakowski V; Lindner D
J Med Internet Res; 2022 Feb; 24(2):e29124. PubMed ID: 35200148
[TBL] [Abstract] [Full Text] [Related]
17. Feasibility of a snowball sampling survey to study active surveillance for thyroid microcarcinoma treatment among endocrinologists and surgeons of Brazil.
Silva IMD; Nogueira TQDS; Couto DN; Lima PCTM; Bonfim NSC; Sousa IGV; Telles ACT; Hecht F; Alkmim NR; Penna GCE; Ferraz C; Tomimori E; Ramos HE
Braz J Otorhinolaryngol; 2022; 88 Suppl 4(Suppl 4):S163-S169. PubMed ID: 35177356
[TBL] [Abstract] [Full Text] [Related]
18. Impact of hemolysis on multi-OMIC pancreatic biomarker discovery to derisk biomarker development in precision medicine studies.
Searfoss R; Shah P; Ofori-Mensa K; Bussberg V; Tolstikov V; Greenwood B; Li H; Richardson K; Miller GM; DeCicco C; Granger E; Rodrigues LO; Grund EM; Moser AJ; Sarangarajan R; Narain NR; Kiebish MA
Sci Rep; 2022 Jan; 12(1):1186. PubMed ID: 35075163
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of Combined cancer Markers With Lactate Dehydrogenase and Application of Machine Learning Algorithms for Differentiating Benign Disease From Malignant Ovarian cancer.
Jeong S; Son DS; Cho M; Lee N; Song W; Shin S; Park SH; Lee DJ; Park MJ
Cancer Control; 2021; 28():10732748211033401. PubMed ID: 34923833
[TBL] [Abstract] [Full Text] [Related]
20. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer.
Ladekarl M; Rasmussen LS; Kirkegård J; Chen I; Pfeiffer P; Weber B; Skuladottir H; Østerlind K; Larsen JS; Mortensen FV; Engberg H; Møller H; Fristrup CW
Acta Oncol; 2022 Mar; 61(3):277-285. PubMed ID: 34879787
[TBL] [Abstract] [Full Text] [Related]
[Next]
